L-Glutamine
|
Basic information |
| Metabolite name | L-Glutamine |
 | HMDB0000641 |
 |
C00064 |
 |
5961 |
| Synonyms | Gln; |
| No. of studies | 126 |
|
Basic information |
| Metabolite name | L-Glutamine |
| HMDB0000641 |
|
C00064 |
|
5961 |
| Synonyms | Gln; |
| No. of studies | 126 |
|
Relationship between L-Glutamine and depression (count: 126) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M003 | Type1 | day 9 CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M003 | Type1 | day 27 CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M016 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M018 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M020 | Type1 | CUMS group vs. control group | Heart | Sprague-Dawley rat | Down |
| Study M021 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M027 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M027 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Down |
| Study M031 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M035 | Type1 | depressed suicide attempters group vs. control group | Plasma | Human | Down |
| Study M047 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M047 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M050 | Type3 | 14h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M059 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M059 | Type2 | Xiaoyaosan-treated depressed group 13-week vs. baseline | Plasma | Human | Down |
| Study M062 | Type1 | CUMS group vs. control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M066 | Type1 | CUMS vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + high dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + middle dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M069 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M071 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6N mouse | Up |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M076 | Type2 | CUMS + Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M082 | Type3 | medium dose of DG group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M082 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M083 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M092 | Type1 | LPS group vs. control group | Prefrontal cortex | CD-1 mouse | Up |
| Study M093 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M093 | Type2 | paroxetine group vs. baseline | Serum | Human | Down |
| Study M100 | Type1 | CS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M1010 | Type2 | CUMS + crocetin group vs. CUMS group | Faece | ICR mouse | Up |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1040 | Type2 | CUMS + Roseburia inulinivorans group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1044 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Brain | CD-1 mouse | Down |
| Study M1048 | Type2 | adult high-fat diet + probiotic group vs. adult high-fat diet group | Brain | CD-1 mouse | Up |
| Study M1048 | Type3 | adult probiotic group vs. adult control group | Brain | CD-1 mouse | Up |
| Study M1076 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M1076 | Type2 | depression group, post Shuganjieyu treatment vs. baseline | Plasma | Human | Up |
| Study M1086 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1095 | Type1 | CUMS group vs. control group | Faece | ICR mouse | Down |
| Study M1095 | Type2 | CUMS + matrine group vs. CUMS group | Faece | ICR mouse | Up |
| Study M1098 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1098 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1129 | Type1 | high dose of perfluorooctane sulfonate group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M115 | Type2 | MDD treated group 8-week vs. baseline | Plasma | Human | Up |
| Study M119 | Type1 | LH group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M120 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M131 | Type1 | LH group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M131 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M137 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M137 | Type2 | CUMS + hypericin group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M137 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M164 | Type1 | depressed group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M165 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M177 | Type3 | scopolamine group vs. control group | Medial prefrontal cortex | Sprague-Dawley rat | Up |
| Study M177 | Type3 | ketamine group vs. control group | Medial prefrontal cortex | Sprague-Dawley rat | Up |
| Study M177 | Type3 | Ro 25-6981 group vs. control group | Medial prefrontal cortex | Sprague-Dawley rat | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M182 | Type1 | CUS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M182 | Type2 | CUS + riluzole group vs. CUS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M187 | Type1 | depressed group vs. control group | Cerebrospinal fluid | Human | Up |
| Study M188 | Type1 | CFSS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M194 | Type1 | CFSS group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M195 | Type1 | female early life stress group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M195 | Type1 | male early life stress group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M204 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Up |
| Study M205 | Type1 | CUMS group vs. control group | Hippocampus | Mouse | Down |
| Study M205 | Type2 | CUMS + XYS group vs. CUMS group | Hippocampus | Mouse | Up |
| Study M205 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Mouse | Up |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Up |
| Study M209 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M258 | Type1 | diabetes with depression group vs. diabetes without depression group | Subcortical nuclei | Human | Down |
| Study M453 | Type1 | depression group vs. control group | Putamen | Human | Up |
| Study M454 | Type2 | vascular depression model + YXST group vs. vascular depression model group | Hippocampus | ICR mouse | Up |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Down |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M465 | Type2 | ketamine-treated group vs. saline-treated group | Prefrontal lobe | Human | Up |
| Study M473 | Type1 | high-fat diet group vs. control group | Striatum | C57BL/6J mouse | Down |
| Study M474 | Type1 | olfactory bulbectomy group vs. control group | Plasma | C57BL/6J mouse | Down |
| Study M478 | Type3 | ketamine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Hippocampus | Wistar rat | Down |
| Study M481 | Type1 | SD group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M481 | Type2 | SD + ketamine group vs. SD group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M483 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M514 | Type3 | ketamine group vs. vehicle group at 14 h | Hippocampus | C57BL/6 mouse | Down |
| Study M516 | Type1 | SMG-treated group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M519 | Type1 | susceptible group vs. control group | Amygdala | C57BL/6N mouse | Down |
| Study M528 | Type2 | CUS + fluoxetine group vs. CUS group | Frontal cortex | FVB mouse | Down |
| Study M539 | Type1 | LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M539 | Type2 | LPS+ Dl-3-n-butylphthalide group vs. LPS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + low dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M553 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M553 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M553 | Type2 | CUMS + venlafaxine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M571 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Up |
| Study M574 | Type1 | CMS + n-3 PUFA deficiency group vs. control + n-3 PUFA deficiency group | Hippocampus | Sprague-Dawley rat | Up |
| Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Urine | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 40-49 | Plasma | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 40-49 | Urine | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 20-29 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Plasma | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 30-39 | Urine | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
| Study M584 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + high dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + low dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M591 | Type1 | LPS group vs. control group | Hippocampus | CD-1 mouse | Up |
| Study M591 | Type1 | LPS group vs. control group | Prefrontal cortex | CD-1 mouse | Up |
| Study M592 | Type1 | CUMS group vs. control group, NMR | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + low dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + venlafaxine group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M595 | Type1 | CRS group vs. control group | Nucleus accumbens | C57BL/6J mouse | Down |
| Study M595 | Type2 | CRS + acetyl-L-carnitine group vs. CRS group | Nucleus accumbens | C57BL/6J mouse | Up |
| Study M605 | Type1 | LPS group vs. control group | Striatum | Fisher 344 rat | Down |
| Study M605 | Type1 | LPS group vs. control group | Hippocampus | Fisher 344 rat | Down |
| Study M614 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M614 | Type2 | CUMS + resistance training group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M614 | Type2 | CUMS + aerobic training group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M620 | Type1 | MDD group vs. control group | Temporal lobe | Human | Up |
| Study M620 | Type1 | MDD group vs. control group | Frontal lobe | Human | Up |
| Study M630 | Type2 | acupuncture + antidepressant group, post vs. before treatment | Urine | Human | Up |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Up |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Down |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M636 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M636 | Type2 | CUMS + Shugan group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M636 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M646 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Up |
| Study M671 | Type1 | CUMS group vs. control group | Striatum | Sprague-Dawley rat | Down |
| Study M672 | Type1 | SMG group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M672 | Type2 | SMG + paroxetine group vs. SMG group | Urine | Sprague-Dawley rat | Down |
| Study M672 | Type2 | SMG + Hemerocallis citrina extracts group vs. SMG group | Urine | Sprague-Dawley rat | Down |
| Study M680 | Type1 | 5-fluorouracil group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M720 | Type1 | CUMS susceptible group vs. control group | Habenula | Sprague-Dawley rat | Down |
| Study M738 | Type1 | CMS + Xiaoyaosan group vs. CMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M738 | Type1 | CMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M740 | Type1 | CUMS group vs. control group | Soleus muscle | Sprague-Dawley rat | Down |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M788 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M815 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + high dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M815 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M840 | Type1 | A1/A2 beta-casein group vs. control group | Frontal cortex | Wistar rat | Down |
| Study M850 | Type1 | reserpine group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M873 | Type1 | ovariectomy + CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M873 | Type2 | ovariectomy + CUMS + Xiang-Su volatile oil group vs. ovariectomy + CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M882 | Type1 | CUMS group vs. control group | Jejunum | Sprague-Dawley rat | Down |
| Study M882 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M885 | Type1 | CMS-vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M896 | Type1 | eating disorders with MDD group vs. eating disorders without MDD group | Plasma | Human | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Cerebrospinal fluid | Human | Down |
| Study M921 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M943 | Type1 | CUMS group vs. control group | Liver | ICR mouse | Down |
| Study M943 | Type2 | CUMS + middle dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Up |
| Study M943 | Type2 | CUMS + fluoxetine group vs. CUMS group | Liver | ICR mouse | Up |
| Study M947 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M947 | Type2 | CUMS + high dose of Chaigui granules group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M947 | Type2 | CUMS + middle dose of Chaigui granules group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M969 | Type1 | CUMS group vs. control group | Hippocampus | ICR mouse | Up |
| Study M969 | Type2 | CUMS + Changyu Daotan Decoction group vs. CUMS group | Hippocampus | ICR mouse | Down |
| Study M972 | Type1 | CRS + irradiation group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M972 | Type2 | CRS + irradiation + paeoniflorin group vs. CRS + irradiation group | Serum | Sprague-Dawley rat | Up |
| Study M972 | Type2 | CRS + irradiation + albiflorin group vs. CRS + irradiation group | Serum | Sprague-Dawley rat | Up |
| Study M972 | Type2 | CRS + irradiation + Paeoniae Radix Alba group vs. CRS + irradiation group | Serum | Sprague-Dawley rat | Up |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Up |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running group vs. Abeta oligomer group | Serum | ICR mouse | Up |
| Study M987 | Type1 | chronic restraint stress group vs. control group | Medial prefrontal cortex | C57BL/6 mouse | Down |
| Study M988 | Type1 | methionine sulfoximine group vs. control group | Medial prefrontal cortex | C57BL/6 mouse | Down |
| Study M989 | Type1 | chronic restraint stress group vs. control group | Medial prefrontal cortex | C57BL/6 mouse | Down |
| Study M989 | Type2 | chronic restraint stress + glutamine diet group vs. chronic restraint stress group | Medial prefrontal cortex | C57BL/6 mouse | Up |